Daiwa Securities Group Inc. Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Daiwa Securities Group Inc. purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,400 shares of the medical equipment provider’s stock, valued at approximately $1,269,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Clearbridge Investments LLC raised its stake in Lantheus by 45.4% in the fourth quarter. Clearbridge Investments LLC now owns 538,782 shares of the medical equipment provider’s stock valued at $33,404,000 after buying an additional 168,114 shares during the period. South Dakota Investment Council raised its stake in Lantheus by 139.3% in the fourth quarter. South Dakota Investment Council now owns 27,317 shares of the medical equipment provider’s stock valued at $1,694,000 after buying an additional 15,900 shares during the period. Silverberg Bernstein Capital Management LLC bought a new stake in Lantheus in the fourth quarter valued at approximately $1,385,000. Boston Partners raised its stake in Lantheus by 9.6% in the fourth quarter. Boston Partners now owns 562,125 shares of the medical equipment provider’s stock valued at $34,344,000 after buying an additional 49,195 shares during the period. Finally, Los Angeles Capital Management LLC raised its stake in Lantheus by 166.4% in the first quarter. Los Angeles Capital Management LLC now owns 42,476 shares of the medical equipment provider’s stock valued at $2,644,000 after buying an additional 26,530 shares during the period. Institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on LNTH shares. JMP Securities upped their target price on Lantheus from $100.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday. B. Riley upped their target price on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. Mizuho increased their price target on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Finally, Truist Financial increased their price target on Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $104.17.

Lantheus Stock Up 36.7 %

Shares of LNTH opened at $106.18 on Thursday. The stock has a market capitalization of $7.36 billion, a price-to-earnings ratio of 16.21 and a beta of 0.51. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $106.99. The stock has a fifty day moving average of $80.10 and a 200-day moving average of $66.95.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The firm had revenue of $369.98 million during the quarter, compared to the consensus estimate of $349.46 million. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the sale, the chief accounting officer now directly owns 62,898 shares in the company, valued at approximately $4,836,227.22. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the sale, the chief accounting officer now directly owns 62,898 shares in the company, valued at approximately $4,836,227.22. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Daniel Niedzwiecki sold 12,873 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $79.86, for a total value of $1,028,037.78. Following the completion of the sale, the insider now owns 80,244 shares of the company’s stock, valued at $6,408,285.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,269 shares of company stock worth $2,557,300. Company insiders own 2.10% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.